Navigation Links
MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference & Exhibition
Date:10/16/2009

WASHINGTON, Oct. 16 /PRNewswire/ -- MedImmune announced today it will present four abstracts at the American Academy of Pediatrics (AAP) 2009 National Conference & Exhibition that add to the company's growing body of research on the burden of respiratory syncytial virus (RSV) on children, as well as pediatric infectious disease prevention.

"With influenza and RSV becoming more widespread this time of year, it remains important to better understand the impact of infectious diseases on pediatric health and the healthcare system, as well as what we can do to prevent illness," said Alexander A. Zukiwski, M.D., executive vice president and chief medical officer. "The data being presented at the conference build on our extensive foundation of research and help advance innovative solutions for preventing illnesses that negatively impact the health of children."

MedImmune abstracts to be presented at AAP on RSV include:

  • "Late Breaking Trial: A Randomized Controlled Trial of RSV Prophylaxis with Motavizumab vs Palivizumab in Young Children with Hemodynamically Significant Congenital Heart Disease."

Feltes, T. et al., Oral Presentation; 9:30 AM - October 18, 2009; H2019 Section on Cardiology & Cardiac Surgery Program -- Washington Convention Center, Room 201

BACKGROUND: Congenital heart disease (CHD) patients are at high risk of complications from RSV lower respiratory infection and may benefit from passive immunoprophylaxis. Motavizumab is an investigational RSV-specific monoclonal antibody that is currently being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. This randomized, double-blind, active-controlled clinical trial evaluated the safety and tolerability of motavizumab in children with congenital heart disease -- a population at high risk for serious RSV disease. Secondary objectives sought to determine the effect of motavizumab on rates of RSV-related hospitalization and RSV-specific lower respiratory tract infections, as well as describe motavizumab's pharmacokinetics and immune response.

  • "Serious Early Childhood Wheezing Following Respiratory Syncytial Virus Lower Respiratory Tract Infection During Infancy Among Preterm Infants"

Romero, JR et al (presenter: Hasan Jafri, MD) [(Friday, October 16, 2009; Room 145 (Washington Convention Center)]

BACKGROUND: Prior studies have suggested that RSV infection is associated with the development of recurrent wheezing in early childhood. However, these studies have had limited sample sizes and lacked laboratory confirmation. This retrospective cohort study sought to determine the relationship between medically attended RSV and recurrent wheezing in the third year of life. Charts of nearly 90,000 infants born at 32 weeks gestation or greater were analyzed for evidence of recurring wheezing and RSV infection, and laboratory testing for RSV was confirmed.

  • "Increased Medical Costs and Use within a Year After Respiratory Syncytial Virus Lower Respiratory Tract Infection Among Commercially-Insured Late-Preterm Infants"

Palmer, L et al (presenter: Lisa Palmer, MD) [(Friday, October 16, 2009; Room 145 Washington Convention Center)]

BACKGROUND: RSV is the leading cause of hospitalization for infants up to the age of one, and is responsible for one of every 13 visits to a pediatrician and one of every 38 emergency room trips for children up to the age of five. This burden on the healthcare system has associated costs. This retrospective cohort study evaluated the total healthcare costs and use of services from infants born between 33 - 36 weeks gestation infected with RSV lower respiratory tract infection (LRI). These late-preterm infants were compared with a control group of infants without RSV LRI, all of whom were commercially insured.

MedImmune abstracts to be presented at AAP on influenza include:

  • Survey of Physician-Led Influenza Immunization Programs in Schools

Harry F. Hull, M.D., HF Hull & Associates, Oral Presentation: October 19; 11:45-11:55 AM Session: Council on School Health

BACKGROUND: The American Academy of Pediatrics, American Academy of Family Physicians, and the Advisory Committee on Immunization Practices now recommend annual influenza immunizations for all children aged six months to 18 years. School-located immunization programs (SIPs) may offer an efficient, less costly means to reach large numbers of school-aged children. There have been reports of physician-led SIPs conducted independently from public health departments, but little is known about these programs. This study documented the experience of physician-led SIPs for the benefit of other physicians considering organizing SIPs.

Additional information about the 2009 AAP National Conference & Exhibition can be found at http://www.aap.org/nce/.

About Palivizumab

Palivizumab is a prescription medication that is used to help prevent a serious lung disease caused by respiratory syncytial virus (RSV) in children at high risk. It is given as a shot, usually in the thigh muscle, each month during the RSV season. Children who develop an RSV infection while receiving palivizumab should continue the monthly dosing schedule throughout the season.

Palivizumab should not be used in patients with a history of a severe allergic reaction to palivizumab or its ingredients. Cases of severe allergic reactions such as anaphylaxis and other types of hypersensitivity reactions have been reported with Synagis. These reactions may occur when any dose of Synagis is given, not just the first one. Very low platelet counts may occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Common side effects may include fever, cold-like symptoms (upper respiratory infection) including runny nose and ear infection, and rash. Other possible side effects include skin reactions around the area where the shot was given (like redness, swelling, warmth or discomfort). In children born with certain types of heart disease, other possible side effects include bluish color of the skin, lips or under fingernails and abnormal heart rhythms. These are not all the possible side effects of Synagis.

For full prescribing information for palivizumab (tradename Synagis(®)), see the company's website at: http://www.medimmune.com/pdf/products/synagis_pi.pdf

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, MedImmune aims to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

SOURCE MedImmune


'/>"/>
SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
2. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
3. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
4. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
5. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
6. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
7. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
8. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
9. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
10. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
11. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... FinancialBuzz.com News Commentary   ... Medical cannabis products around the world are projected to gain popularity. A ... market will reach a value of USD 55.8 billion by 2025. ... growing industry. By the end of 2016, 28 states have now laws ... conservative states like Arkansas and North ...
(Date:3/24/2017)... -- Global Ampoules Market report provides a ... and industry chain structure. The Ampoules market analysis is ... landscape analysis, and major regions, development status. ... Complete ... 10 company profiles and 183 tables and figures is ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly and ... plans to invest $850 million in its U.S. ... across its U.S. enterprise, including research laboratories, manufacturing ... are being driven by demand for Lilly products, ... medicines in development targeting cancer, pain, diabetes and ...
Breaking Medicine Technology:
(Date:3/24/2017)... Calif. (PRWEB) , ... March 24, 2017 , ... ... raised over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on ... instant demand for the product – with nearly 2,000 consumers (and counting) already ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to ... critical historical facts, cultural practices, goods, services, and societal issues tend to appreciate and ... into the popular practice of utilizing running events for causes around the world. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a ... will interrelate. “End Time GPS” is the creation of published author, Wesley Gerboth, ... working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares the ...
(Date:3/23/2017)... ... 23, 2017 , ... A recent report from the National Council on Teacher ... NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at 221 ... the U.S. It argues that this higher bar should be set by states, by ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The IoT (Internet ... WiFi connectivity are making a huge impact on businesses and individual consumers alike. ... the IoT will have a value anywhere from $4 trillion to $11 trillion dollars ...
Breaking Medicine News(10 mins):